RallyRaider Posted - 10 hours ago

$PSTX maybe this starts going somewhere now? wrote it off earlier. MGMT isnt too capable

Sandpiper22 Posted - 1 day ago

$PSTX always knew you could do it (March 8 seems like forever ago).

Observationalist Posted - 1 day ago

$PSTX Running back to the channel. 👀 $3.78

LabPsycho Posted - 1 day ago

$PSTX Based on their track record of stiffing shareholders, is it unreasonable to think they would do yet another InstaDilution(TM) on the slightest good news?

Stocks4thought Posted - 1 day ago

$ELDN Sexy ot $slno $stok $pstx $vktx

_StockTrader Posted - 1 day ago

Real-Time Stock Data $PSTX Price: 3.46 Volume: 672618 Market Cap: 333433024 PE Ratio: -1.9325843 Powered by: AITX

Stocks4thought Posted - 1 day ago

$MRKR I remember when you moved a point a day------------soon dear deer points$$ ot $STOK $PSTX $MRKR $SLNO $ELDN

Stocks4thought Posted - 1 day ago

$MRKR Major mover shortly 0t $STOK $PSTX $ELDN $SLNO

AlbertSan Posted - 1 day ago

$PSTX flying under the radar

Stocks4thought Posted - 1 day ago

$ELDN Undervalued ot $STOK $PSTX $SLNO $PROK

the_real_Joker Posted - 1 day ago

$PSTX Depends on CIO's action. Last "sweet report" endet up in a instant offering and hard dip.

Bandit246 Posted - 1 day ago

$PSTX imagine if we had volume.

Stocks4thought Posted - 1 day ago

$PSTX Sweet

radonco Posted - 2 days ago

$PSTX no mention of advancing allo car-t targeting psma for prostate cancer…hope they are still prioritizing this…perhaps this will be further developed in collaboration with astellas subsidiary xyphos

dkm1111 Posted - 2 days ago

$PSTX "We see 2024 as a breakout year for Poseida as we make great strides across our cell therapy and genetic medicine programs and continue to cultivate and expand high value collaborations that highlight Poseida's role as the partner of choice in allogeneic CAR-T," said Kristin Yarema, Ph.D., President and Chief Executive Officer of Poseida Therapeutics. "The promising updates from our BCMA program at AACR 2024 reinforce our belief that P-BCMA-ALLO1 has the potential to treat a broad range of patients with multiple myeloma, including those who are BCMA-therapy naive and those who have relapsed or are refractor y to BCMA-targeted therapies such as autologous CAR-T or T-cell engaging bispecifics. We continue to advance our MUC1-C solid tumor and CD19CD20 B-cell malignancy programs and are on track to provide updates across our wholly owned and Roche-partnered CAR-T programs in the second half of 2024."

Bandit246 Posted - 2 days ago

$PSTX sweet report…. do we dip or surge?

DonCorleone77 Posted - 2 days ago

$PSTX Poseida Therapeutics reports Q1 EPS (25c), consensus (42c) Reports Q1 revenue $28.1M, consensus $11.67M. As of March 31, 2024, the Company's cash, cash equivalents and short-term investments balance was $198.6 million. In addition, the Company will receive $50 million from the recent Astellas research collaboration and $15 million from a recent milestone achievement within the Roche collaboration. The Company expects that its cash, cash equivalents and short-term investments together with these and other remaining near-term milestones and other payments from Roche will be sufficient to fund operations into the second half of 2025. Potential additional payments under the Roche Collaboration Agreement and/or potential additional business development could further extend cash runway. "We see 2024 as a breakout year for Poseida as we make great strides across our cell therapy and genetic medicine programs and continue to cultivate and expand high value collaborations that highlight Poseida's role as the partner of choice in allogeneic CAR-T," said Kristin Yarema, Ph.D., President and Chief Executive Officer of Poseida Therapeutics. "The promising updates from our BCMA program at AACR 2024 reinforce our belief that P-BCMA-ALLO1 has the potential to treat a broad range of patients with multiple myeloma, including those who are BCMA-therapy naive and those who have relapsed or are refractory to BCMA-targeted therapies such as autologous CAR-T or T-cell engaging bispecifics. We continue to advance our MUC1-C solid tumor and CD19CD20 B-cell malignancy programs and are on track to provide updates across our wholly owned and Roche-partnered CAR-T programs in the second half of 2024."

Stock_Titan Posted - 2 days ago

$PSTX Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 https://www.stocktitan.net/news/PSTX/poseida-therapeutics-provides-updates-and-financial-results-for-the-5oz67d0lhx36.html

SirLordy Posted - 2 days ago

$PSTX

dkm1111 Posted - 2 days ago

$PSTX

SpiderR Posted - 1 week ago

$PSTX https://investors.poseida.com/news-releases/news-release-details/poseida-highlights-strong-progress-its-genetic-medicine-programs

Stock_Titan Posted - 1 week ago

$PSTX Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting https://www.stocktitan.net/news/PSTX/poseida-highlights-strong-progress-on-its-genetic-medicine-programs-b2e6cqtzdb07.html

Sandpiper22 Posted - 1 week ago

$CRBU $PSTX $PRME $EDIT $ALLO all cheap and oversold. Holding each going forward this summer and beyond 📈

the_real_Joker Posted - 1 week ago

$PSTX 100% up? godot?

Bandit246 Posted - 1 week ago

$PSTX The time has come.

dkm1111 Posted - 1 week ago

$PSTX ER today after market.

Stockswingalert Posted - 1 week ago

$PSTX $XBI nice bounce, see if this can break and hold some gains now that it had a solid pr

DeepDown Posted - 1 week ago

$PSTX this thing may get a bo bid soon

Stockswingalert Posted - 2 weeks ago

$PSTX $XBI weekly trend line bounce, holding up well

the_real_Joker Posted - 2 weeks ago

$PSTX All day long, price pressing was seen at low volume phases. After the News with this 600M Deal, this has to go further up > 100% https://www.marketscreener.com/quote/stock/POSEIDA-THERAPEUTICS-INC-109519711/news/Poseida-Therapeutics-to-Receive-Up-to-600-Million-in-Cancer-Gene-Therapy-Research-Development-Deal-46602262/